Wound debridement compositions containing seaprose and methods of wound treatment using same

Patent metadata

Field	Value
Publication number	US-10206982-B2
Application number	US-201715417680-A
Country	US
Kind code	B2
Filing date	Jan 27, 2017
Priority date	May 12, 2011
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.

First claim

The invention claimed is:

1. A method of debriding a wound that includes necrotic tissue, the method comprising applying to the wound a composition comprising a semi-alkaline protease produced by the fermentation of the fungus Aspergillus melleus (Seaprose), wherein application of the composition debrides necrotic tissue in the wound.

2. The method of claim 1 , wherein the necrotic tissue is an eschar.

3. The method of claim 1 , wherein the composition is topically applied to the wound.

4. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable topical carrier.

5. The method of claim 1 , wherein the wound is a chronic wound.

6. The method of claim 5 , wherein the chronic wound is a diabetic foot ulcer, a venous leg ulcer, an arterial leg ulcer, a decubitus ulcer, a stasis ulcer, a dermal ulcer, a burn, or a pressure ulcer.

7. The method of claim 1 , wherein the composition includes 0.1 to 8% by weight of Seaprose.

8. The method of claim 7 , wherein the composition includes 0.5 to 1.5% by weight of Seaprose.

9. The method of claim 1 , wherein the Seaprose is isolated or purified Seaprose.

10. The method of claim 1 , wherein the composition is formulated as a gel, cream, or ointment.

11. The method of claim 1 , wherein the composition further comprises glycerin polyacrylate clatharate, glycerin, hydroxyethylcellulose, an emulsifying wax, or petrolatum, or any combination thereof.

12. The method of claim 1 , wherein the composition is injected into the wound.

13. The method of claim 12 , wherein the composition further comprises a pharmaceutically acceptable injectible carrier.

14. The method of claim 1 , wherein the semi-alkaline protease has a molecular weight of about 31 kDa.

15. The method of claim 1 , wherein the composition does not include any other enzymatic debridement agents other than Seaprose.

Assignees

• Smith & Nephew Orthopaedics Ag

Inventors

• Shi Lei
• Jovanovic Aleksa
• Carson Dennis

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K38/482 Primary

  Serine endopeptidases (3.4.21) · CPC title

• A61K47/38

  Cellulose; Derivatives thereof · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title